EASO

Easo Biopharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing innovative biologics for immune-mediated diseases. The company focuses on therapeutic areas including allergy, inflammation, and ophthalmology, utilizing its proprietary antibody discovery platforms. Its lead candidate, AS101, is a monoclonal antibody targeting IL-4Rα currently in mid-to-late-stage clinical trials for atopic dermatitis and asthma. Easo's pipeline also includes programs targeting IL-5 and IL-17, positioning the company as a significant player in the Chinese immunology space. By focusing on validated pathways with optimized antibody engineering, Easo aims to deliver high-quality, cost-effective treatments for chronic inflammatory conditions.